Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Chemotherapy-Related Nausea and/or Vomit...
Phase Not Applicable
Enrollment 70
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of fatigue and CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with fatigue and CIN.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo collection of stool and blood samples
  • Other: Questionnaire Administration — Complete questionnaires

Primary Outcomes

  • Number of patients approached (Up to 24 months)
  • Number of patients enrolled (Up to 24 months)
  • Number of patients who completed the questionnaires at both assessments (At baseline and 3-5 days after initiation of chemotherapy)
  • Number of patients who provided stool samples at both assessments (At baseline and 3-5 days after initiation of chemotherapy)
  • Bacterial composition of stool samples (Up to study completion)
  • Differences in demographic between patients who do and do not report fatigue and CIN (Up to study completion)
  • Differences in clinical characteristics between patients who do and do not report CIN (Up to study completion)
  • Differences in comorbidities between patients who do and do not report CIN (Up to study completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-04-14
Completion: 2027-03-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Brenda J. Ernst, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic Health System in Albert Lea
Mina Hanna, MD
Mayo Clinic Health System in Albert Lea
Clinical Trials Referral Office
612-624-2620
mayocliniccancerstudies@mayo.edu
Mayo Clinic Health System in Mankato
Interventions
  • Procedure: Biospecimen Collection — Undergo collection of stool and blood samples
  • Other: Questionnaire Administration — Complete questionnaires
Study Locations (5 sites)
Mayo Clinic in Arizona, Scottsdale, Arizona 85259 United States
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota 56007 United States
Mayo Clinic Health System in Mankato, Mankato, Minnesota 56001 United States
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Subjects with a diagnosis of early stage breast cancer planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic Health Systems including Mankato and Albert Lea; Mayo Clinic Arizona; Mayo Clinic Rochester (Minnesota); and Mayo Clinic Florida * At least 20 years of age * Last chemotherapy more than 3 years ago * Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies Exclusion Criteria: * Metastatic disease * Concurrent radiation therapy * Concurrent antibiotic treatment
Conditions Breast Cancer
Phase PHASE4
Enrollment 2413
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Studies on postoperative adjuvant albumin paclitaxel in domestic breast cancer patients are less reported, especially in large samples, and more studies focus more on the safety and tolerability of albumin paclitaxel use. Head-to-head studies of white violet and docetaxel are not supported by data at this time, but some studies have shown that docetaxel-induced long-term Other adverse effects such as myelosuppression, hepatotoxicity and hypersensitivity reactions can have a serious impact on quality of life. Therefore, this study aims to analyse the efficacy and safety of albumin paclitaxel and docetaxel in the adjuvant treatment of breast cancer in a large randomized controlled trial, and to further analyse the efficacy and safety of albumin paclitaxel in combination with chemotherapy for postoperative breast cancer in different subtypes of breast cancer patients, in order to obtain more realistic data and provide new treatment options for breast cancer patients.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Docetaxel — 75 mg/m2, d1, q3w,6 cycles
  • Drug: Carboplatin — AUC 6, d1, q3w,6 cycles
  • Drug: Trastuzumab — starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
  • Drug: Pertuzumab — starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
  • Drug: Nab paclitaxel — 220 mg/m2, d1, q3w,6 cycles
  • Drug: Epirubicin — 90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
  • Drug: Cyclophosphamide — 600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
  • Drug: Docetaxel — 100 mg/m2, d1, q3w × 4 cycles

Primary Outcomes

  • 5-year DFS (5-years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-07-10
Completion: 2027-12-20
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2413 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Yiding CHEN
13605719519
ydchen@zju.edu.cn
Huihui CHEN
571-87784527
huihuicyj@zju.edu.cn
Yiding Chen
571-87784527
ydchen@zju.edu.cn
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Interventions
  • Drug: Docetaxel — 75 mg/m2, d1, q3w,6 cycles
  • Drug: Carboplatin — AUC 6, d1, q3w,6 cycles
  • Drug: Trastuzumab — starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
  • Drug: Pertuzumab — starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
  • Drug: Nab paclitaxel — 220 mg/m2, d1, q3w,6 cycles
Study Locations (1 sites)
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≥18 years; 2. Histopathologically or cytologically confirmed breast cancer patients with the following characteristics:1. stage I to III breast cancer; 2. operable primary lesion with no evidence of distant metastasis (M0); 3. known hormone receptor status (estrogen receptor \[ER\], progesterone receptor \[PR\]) and HER2 status with known Ki67 expression levels; (ER/PR positive defined as stained cells \>1%, HER2 positive defined as IHC 3+ or IHC 2+ with a positive FISH test); 4. Triple-negative breast cancer (TNBC): ER/PR negative, HER2 negative; tumor \>2cm or lymph node metastasis with clear postoperative pathological evidence; Luminal breast cancer: ER\>1%, HER2 negative, postoperative pathological evidence definite lymph node metastasis (different adjuvant chemotherapy regimens depending on whether the lymph nodes are N1 or N2-3); HER2-positive breast cancer: HER2-positive, regardless of ER/PR status; (the above classification determines enrollment and adjuvant therapy, and does not represent the corresponding molecular typing definition); 5. Patients who have undergone breast cancer resection and systemic intrathoracic lymph node dissection; surgical resection is R0 resection; patients who need postoperative adjuvant chemotherapy as judged by the investigator; 6. Start of adjuvant therapy within 21 days of the time of surgery is appropriate ; 7. ECOG physical fitness score of 0-1 with an expected survival of \>6 months ; 8. Patients have not been treated with a paclitaxel regimen prior to enrolment ; 9. Adjuvant chemotherapy should not be performed concurrently with endocrine therapy drugs such as tamoxifen/aromatase inhibitors or postoperative radiotherapy; 10. Women of childbearing age must have taken reliable contraceptive measures, or performed a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and be willing to use appropriate contraceptives during the trial and 8 weeks after the last dose of the trial drug; 11. Electrocardiogram (ECG) and echocardiography must confirm normal cardiac function within 3 months prior to randomization. Left ventricular ejection fraction (LVEF) must be ≥55% for patients receiving anthracycline-containing chemotherapy regimens and targeted therapy ; 12. Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal; AST and ALT ≤3 times the upper limit of normal; total bilirubin ≤1.5 times the upper limit of normal, or ≤2.5 times the upper limit of normal when the patient has Gilbert's syndrome ; 13. Bone marrow function: neutrophils≥1.5×109/L, platelets≥100×109/L, hemoglobin≥90g/L; 14. Able to comply with outpatient treatment, laboratory monitoring and necessary clinical visits during the study period; 15. Subjects have the ability to understand, agree and sign the Informed Consent Form (ICF) for the study prior to initiating any protocol-related procedures; subjects have the ability to express consent (if applicable). Exclusion Criteria: 1. Advanced and/or inoperable patients with distant metastasis confirmed by imaging evidence or pathology; 2. Other malignant tumors have occurred in the past 5 years, except for skin cancers of cured cervical carcinoma in situ and non-melanoma; 3. Pregnant or breastfeeding women; patients with childbearing potential who are unwilling or unable to take effective contraceptive measures; 4. The molecular status of ER/PR and HER2 and Ki67 cannot be determined; 5. Patients with CNS metastases or \> grade 1 peripheral neuropathy; 6. Severe cardiovascular disease: Grade II or higher myocardial ischaemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥ 470 ms); Grade III-IV cardiac insufficiency according to NYHA criteria, or cardiac ultrasound indicating a left ventricular ejection fraction (LVEF) of \<50%; 7. Patients with hypertension that cannot be reduced to the normal range after antihypertensive medication (systolic blood pressure\>140 mmHg, diastolic blood pressure\>90 mmHg); 8. Received major surgical operations or suffered severe traumatic injury, fracture or ulcer within 4 weeks of enrollment; 9. Patients with severe myelosuppression at screening; 10. Patients with severe liver dysfunction (Child's Class III) or renal dysfunction at screening ; 11. Arterial/venous thrombotic events such as cardiovascular and cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep vein thrombosis and pulmonary embolism, that occurred within 6 months before randomization; 12. Patients with hypersensitivity to any of the components of albumin paclitaxel, epirubicin, cyclophosphamide, docetaxel, trastuzumab, and pertuzumab; 13. Patients with psychiatric disorders; 14. Subjects who are participating in another clinical study or whose first dose was administered less than 4 weeks (or 5 half-lives of the study drug) from the end of the previous clinical study (last dose) ; 15. The investigator judges other situations that may affect the clinical research and the judgment of the research results and are not suitable for inclusion in the research.
Conditions Advanced Breast Cancer
Phase PHASE2
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Protocol Title: A Phase II open label, umbrella study evaluating the efficacy and safety of Fulvestrant plus DNA damage repair inhibitors in hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Olaparib — Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
  • Drug: Fulvestrant — Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter

Primary Outcomes

  • 6-month progression-free survival (PFS) rate (Duration of response is the time from response to progression or death from any cause whichever is earlier.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-31
Completion: 2025-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Contact Information
Study Contact:
Seock-Ah Im
82-2-2072-0850
moisa@snu.ac.kr
Seoul National University Hospital
Kyung-Hun Lee, MD
Seoul National University Hospital
Dae-Won Lee, MD
Seoul National University Hospital
Interventions
  • Drug: Olaparib — Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
  • Drug: Fulvestrant — Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
Study Locations (1 sites)
Seoul National University Hospital, Seoul, South Korea
Eligibility Criteria
1.1 Inclusion criteria Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply: Informed consent 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. Age 3. Subject must be 19 years of age or older at the time of signing the informed consent form. Type of patient and disease characteristics 4. Patients with HR+/HER2- metastatic or inoperable breast cancer 5. Disease progression following treatment with endocrine therapy(ies) and CDK4/6 inhibitor 6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below * Hemoglobin ≥ 10.0 g/dL. Red blood cell/plasma transfusion is not permitted within 2 week prior to screening assessment. * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. Granulocyte colony-stimulating factor administration is not permitted within 1 week prior to screening assessment. * Platelet count ≥ 100 x 109/L. Platelet transfusion is not permitted within 1 week prior to screening assessment. * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) if no liver metastases; or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN * Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test : Estimated creatinine clearance = (140-age \[years\]) x weight (kg) (x F)a serum creatinine (mg/dL) x 72 a where F=0.85 for females and F=1 for males. 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 8. Patients must have a life expectancy ≥ 16 weeks. 9. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment. Reproduction 10. Postmenopausal or evidence of non-childbearing status for women of childbearing potential. Postmenopausal is defined as: * Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments * Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50 * radiation-induced oophorectomy with last menses \>1 year ago * chemotherapy-induced menopause with \>1 year interval since last menses * surgical sterilisation (bilateral oophorectomy or hysterectomy) OR Pre/peri-menopausal, ie, not meeting the criteria for being post-menopausal. * Pre-/peri-menopausal women can be enrolled if amenable to be treated with monthly LHRH agonists (goserelin or leuprorelin). Participants must have concomitant treatment with LHRH agonists (goserelin or leuprorelin) - which must have been started 3 weeks before Cycle 1 Day 1 - and must be willing to continue on it for the duration of the study. 11. Negative pregnancy test (urine and/or serum) for women of childbearing potential within 28 days of study treatment and confirmed prior to treatment on day 1. 12. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential Specific criteria for each cohort 13. \<For cohort A\> Patients with known germline or somatic mutations of BRCA1 or BRCA2 14. \<For cohort B\> Patients with known somatic mutations of BRCA1, BRCA2, or other DDR genes (including ATM(ataxia telangiectasia mutated), ATR, BRIP1, PALB2, CHEK1, CHEK2, FANC family, RAD51 family, etc.) Patients with alteration in other DDR genes can be discussed with the principal investigator at the molecular tumour board. 1.2 Exclusion criteria Medical conditions 1. As judged by the investigator, any evidence of condition or illness which in the investigator's opinion makes it undesirable for the patient to participate in the trial. 2. Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. 3. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \>500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome. 4. Persistent toxicities (\>Common Terminology Criteria for Adverse Event (CTCAE) v5.0 grade 2) caused by previous cancer therapy, excluding alopecia grade 2. 5. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS(myelodysplastic syndrome)/AML(Acute Myelogenous Leukemia ) 6. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids (up to 10 mg prednisone/day or equivalent) before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days. 7. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent. 8. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. 9. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV). 10. Patients with known active hepatitis (i.e. Hepatitis B or C). * Active hepatitis B virus (HBV) infection is defined by a positive HBV surface antigen (HBsAg) and positive titer for HBV DNA.result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg or deoxyribonucleic acid \[DNA\]-negative) are eligible. * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 11. Underweight populations - ≤30kg 12. History of bleeding diathesis (ie, disseminated intravascular coagulation, clotting factor deficiency) or long-term anticoagulant therapy (although patients treated with anti-platelet therapy and low dose warfarin or other anticoagulant agents such as acenocoumarol are eligible providing they have an international normalised ratio \[INR(international normalized ratio)\] of ≤1.6) Prior/concomitant therapy 13. Any previous treatment with fulvestrant, other study drugs (including olaparib or study drugs in each arms), or other investigational agents directly targeting DNA damage response. 14. Patients receiving any s
Conditions Idiopathic Pulmonary Arterial Hypertensi...
Phase Not Applicable
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No Intervention — No Intervention

Primary Outcomes

  • Change in Right Ventricular (RV) Ejection Fraction (Baseline to 36 months)
  • Change in Right Ventricular (RV) Lipid Content (Baseline to 36 months)
  • Identification of metabolic markers (dihyroxybutyrate, acetylputriscene, hydroxystearate and glucuronate) in the peripheral circulation and coronary sinus. (Baseline to 36 months)
  • Ratio of BMPR2 isoform B/A. (Baseline to 36 months)
  • Change in skeletal muscle lipid content. (Baseline to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-17
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Evan Brittain, MD, MSCI (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Natasha Billard
(434) 851-3306
natasha.billard.1@vumc.org
Evan Brittain, MD, MSCI
(615) 322-4382
evan.brittain@vumc.org
Interventions
  • Other: No Intervention — No Intervention
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion criteria: * ≥ 18 years old * Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations. * Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted. * WHO Functional Class I-III * Ambulatory * Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test Exclusion criteria: * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins * WHO Functional class IV heart failure * Requirement for continuous oxygen * Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test. * Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI
Conditions Major Depressive Disorder, Suicidal Idea...
Phase NA
Enrollment 240
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Genetic: Genetic testing — Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action

Primary Outcomes

  • Clinical phenotype analysis (6 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-01
Completion: 2027-06-30
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Allison Stewart, MA
256-551-4431
allisonstewart@uabmc.edu
Azka Aleezada
205-996-2723
aaleezada@uabmc.edu
University of Alabama at Birmingham
Jennifer Burns, MS
256-551-4677
jenniferburns@uabmc.edu
UAB Huntsville Regional Medical Campus
Interventions
  • Genetic: Genetic testing — Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
Study Locations (2 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35233 United States
UAB Huntsville Regional Medical Campus, Huntsville, Alabama 35294 United States
Eligibility Criteria
Inclusion Criteria: All participants: 1. Physically healthy 2. willing and able to provide informed consent (if under 18 also parent or guardian consent) MDD participants: 1. A definite diagnosis of DSM-5 2. a Children's Depression Rating Scale-Revised (CDRS-R) score \>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \>=4 rated over the last two weeks. Suicide attempt group: 1\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale. Non-psychiatric controls: 1\. No history of any major mental illness (excluding specific phobia) or substance use disorder. Exclusion Criteria: * Exclusion criteria: 1. Pregnancy or lactation 2. post-partum state (being within 2 months of delivery or miscarriage); 3. homicide risk as determined by clinical interview 4. any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine/caffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa. 5. recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months 6. use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.
Conditions Depression
Phase NA
Enrollment 136
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will be comparing brain (neural) activation of depressed adolescent patients before, during and after a course of Behavioral Activation (BA) therapy using functional magnetic resonance imaging (fMRI). In particular, the project seeks to determine whether BA targets different neural mechanisms for behavioral avoidance associated with low motivation as compared to threat avoidance. A group of healthy controls will also be scanned as a comparator group for behavioral and imaging measures.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Behavioral Activation Therapy — Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
  • Behavioral: Baseline assessment procedures — Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.

Primary Outcomes

  • Change in Diagnostic Interview Status (CDRS-R) total score from baseline (Baseline, week 16 post intervention)
  • Change in Adolescent Longitudinal Interval Follow-Up Evaluation (A-LIFE) (Week 8 post intervention (Midpoint), week 16 post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-30
Completion: 2027-05
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: true
Enrollment: 136 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Michael Treadway, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Wade E Craighead, PhD
4047273287
ecraigh@emory.edu
Michael Treadway, PhD
mtreadway@emory.edu
Wade E Craighead, PhD
ecraigh@emory.edu
Emory University
Interventions
  • Behavioral: Behavioral Activation Therapy — Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
  • Behavioral: Baseline assessment procedures — Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
Study Locations (3 sites)
Emory University, Atlanta, Georgia 30322 United States
Facility for Education and Research in Neuroscience (FERN), Atlanta, Georgia 30322 United States
Child and Adolescent Mood Program (CAMP), Atlanta, Georgia 30329 United States
Eligibility Criteria
Inclusion Criteria: * Male and female adolescents ages 15-17; * current MDD diagnosis as determined by K-SADS-PL, * CDRS-R raw score \> 45 (T-score \> 65) at baseline; * estimated full scale IQ \> 80 as determined by the WASI-II; * able to receive outpatient care; * willing to not partake in other psychosocial treatments; * not taking psychotropic medications in the two weeks (four weeks for fluoxetine) prior to consent, with the exception of psychostimulant medication prescribed for the treatment of ADHD. * Additionally, depressed patients must have access to required technology (e.g. smart phone, tablet, or desktop computer) to complete the EMA portion of the study. * Healthy controls cannot not meet criteria for MDD and their CDRS-R raw score must be below 28; T-score \< 52). Exclusion Criteria: * Current or past diagnosis of bipolar, schizophrenia, schizophreniform, schizoaffective disorders, or psychosis NOS; * current diagnosis of developmental disorder, severe conduct disorder, life-threatening anorexia, OCD, or autism-spectrum disorders; * taking psychotropic medications prior to entry; * estimated IQ \< 80; alcohol/drug dependence or abuse within the last 3 months; * potential/confirmed neurological disorder or epilepsy; * claustrophobia; * presence of a medical condition that precludes fMRI; * endorsement of imminent and serious suicidality; * medical conditions that take precedence over the presence of MDD; * pregnancy; * substance use (excluding nicotine) within two weeks of the fMRI scan; * left-handedness; * nicotine use within 3 hours of the fMRI scan; * history of traumatic brain injury or of being unconscious for more than 30 minutes; * a stimulant regime for ADHD which has changed within 30 days of the fMRI scan. * Non-compliance (i.e. \<70% completion) or inability (i.e. lack of smartphone device) to complete the 3 assessment periods of EMA.

The eHealth Diabetes Remission Trial

NCT05491005
Recruiting
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 106
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Overweight patients with type 2 diabetes are offered a total diet replacement with the goal of weight loss and diabetes remission. Study participants are randomised to eHealth follow-up or face-to-face follow-up, but the dietary advice is the same in both groups. A healthy control group with normal glucose tolerance is examined once but is not randomised and does not receive any intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Total diet replacement — Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
  • Behavioral: eHealth — All follow-up through an eHealth application and video meetings.
  • Behavioral: Face-to-face — All follow-up through face-to-face meetings.

Primary Outcomes

  • HbA1c (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-31
Completion: 2028-01-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 106 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Umeå University
Collaborators: Region Västerbotten, Edgar Sjölunds Diabetes Foundation
Principal Investigators:
  • Julia Otten, PhD (PRINCIPAL_INVESTIGATOR) - Umeå University
Contact Information
Study Contact:
Julia Otten, PhD
+46703341559
julia.otten@umu.se
Andreas Stomby, PhD
Bra Liv Råslätt vårdcentral
Katarina Shahedi, MD
Örnsköldsvik hospital
Interventions
  • Behavioral: Total diet replacement — Total diet replacement (850 kcal/day) for 3 months followed by weight maintenance for 21 months.
  • Behavioral: eHealth — All follow-up through an eHealth application and video meetings.
  • Behavioral: Face-to-face — All follow-up through face-to-face meetings.
Study Locations (3 sites)
Bra Liv Råslätt vårdcentral, Jönköping, Sweden
Örnsköldsvik hospital, Örnsköldsvik, Sweden
Department of Public Health and Clinical Medicine, Medicine, Umeå, 90187 Sweden
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes with duration 0-6 years * BMI 27 kg/m2 and higher * HbA1c 43 mmol/mol or higher (48 or higher if without diabetes medication) Exclusion Criteria: * Insulin treatment * Weight loss more than 5 kg during the past 6 months * Diagnosed eating disorder * eGFR \< 30 ml/min/1,73m2 * Myocardial infarction last six months * Severe heart failure (NYHA class III) * Ongoing cancer * Pregnancy * Treatment with antipsychotic drugs
Conditions Pulmonary Hypertension
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Children with pulmonary hypertension (PH) engage in less physical activity than their peers. This is a concern since adult data support exercise as a non-pharmacologic treatment for PH. Despite adult data, therapeutic exercise has not been widely adopted in pediatric PH. Investigators have previously demonstrated that children with PH have less skeletal muscle mass in association with worse exercise performance. Interventions to increase physical activity and skeletal muscle mass may improve exercise performance and quality of life in children with PH. This study will use wearable activity monitoring devices to promote physical activity in a 16-week pilot intervention in children and teenager with PH.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Exercise intervention — 16-week home exercise intervention, enriched by mobile health technology

Primary Outcomes

  • Change in moderate to vigorous physical activity (MVPA) (Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-03
Completion: 2026-12-31
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital of Philadelphia
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Catherine Avitabile, MD
215-590-4040
avitabilec@chop.edu
Catherine Avitabile, MD
avitabilec@chop.edu
Children's Hospital of Philadelphia
Interventions
  • Behavioral: Exercise intervention — 16-week home exercise intervention, enriched by mobile health technology
Study Locations (1 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Age 8-18 years * PH World Health Organization (WHO) diagnostic groups 1, 2, 3, or 4 (pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, chronic thromboembolic PH) * WHO functional class I or II * Ambulatory status * Mean pulmonary to systemic arterial pressure ratio \<0.75 if the patient has not undergone a pulmonary to systemic artery shunt ("Potts" shunt) OR the placement of a Potts shunt ≥ 6 months prior to study enrollment * Stable PH medication regimen for 3 months prior to the intervention * Home Wifi connection * Mobile device in family capable of receiving text messages Exclusion Criteria: * WHO functional class III or IV * Single ventricle physiology * Moderate to severe renal disease (\>stage 3) * Severe hepatic impairment \[aspartate aminotransferase (AST)/alanine transaminase (ALT) \> 2x upper limit of normal\] * Current pregnancy * Significant developmental delay/inability to comply with verbal instructions to complete the study procedures
Conditions Breast Neoplasms, Locally Advanced or Me...
Phase PHASE3
Enrollment 349
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: utidelone — Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
  • Drug: docetaxel — Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Primary Outcomes

  • Progression Free Survival (PFS) (up to 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-06-21
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 349 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Collaborators: Beijing Biostar Pharmaceuticals Co., Ltd., Hunan Cancer Hospital
Contact Information
Study Contact:
shusen wang, MD
+86-020-87342693
wangshs@sysucc.org.cn
shusen wang, MD
+86-020-87342693
wangshs@sysucc.org.cn
Shusen Wang
Quchang OuYang, MD
oyqc1969@126.com
Hunan Cancer Hospital
Interventions
  • Drug: utidelone — Eligible patients will receive treatment with utidelone(40 mg/ m2 /day, D1-5,Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
  • Drug: docetaxel — Eligible patients will receive treatment with docetaxel (75mg/ m2/day, D1, Q3W) , treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study Locations (2 sites)
Shusen Wang, Guangzhou, Gangdong China
Hunan Cancer Hospital, Hunan, Hunan 410000 China
Eligibility Criteria
Inclusion Criteria: * Signed the informed consent form; * Women aged ≥ 18 years; * Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer; * The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative; * Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points; * Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI; * Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization; * No previous chemotherapy for advanced breast cancer ; * For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage; * Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ; * Patients with asymptomatic CNS metastases may be enrolled, if: 1. Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or 2. Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ; * Adequate hematological, hepatic and renal function; * Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment; * Life expectancy of at least 12 weeks; * Patients must be able to participate and comply with treatment and follow up. Exclusion Criteria: * HER-2 positive (IHC 3+, or FISH positive); * Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ; * Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy; * Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study; * Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs; * Symptomatic central nervous system metastases; * Pregnant or lactating women; * Known or suspected hypersensitivity to any of the study drugs or excipients; * Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ; * Any other condition that the investigator considers inappropriate to participate in this trial . * Use of corticosteroids is prohibited.
Conditions Type2diabetes
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Caloric Restriction — Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from "Nutritional Guidelines after Bariatric Surgery". Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake
  • Drug: Hyperglycemic clamp — Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism

Primary Outcomes

  • Rate of leucine oxidation in response to rising glucagon concentrations (240 minutes of study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-15
Completion: 2027-12-31
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Adrian Vella
Principal Investigators:
  • Adrian Vella (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Jeanette Laugen
5072558110
Laugen.Jeanette@mayo.edu
Interventions
  • Behavioral: Caloric Restriction — Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from "Nutritional Guidelines after Bariatric Surgery". Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake
  • Drug: Hyperglycemic clamp — Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * We will recruit up to 20 weight-stable, subjects with type 2 diabetes * BMI ≥ 28 Kg/M2 * Diabetes is managed by diet alone or a combination of oral agents Exclusion Criteria: * History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy. * Active systemic illness or malignancy. * Symptomatic macrovascular or microvascular disease. * Contraindications to MRI (e.g. metal implants, claustrophobia). * Hematocrit \< 35% * TSH \< 0.4 or \> 5.5. * Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.
Conditions Cardiovascular Diseases, Cardiovascular ...
Phase NA
Enrollment 65
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background \& Rationale: Breast cancer (BC) is the most commonly diagnosed malignancy in women worldwide (2.1 million diagnoses in 2018, 25% of new cancer cases). In Canada, early stage BC mortality rates have decreased by 48% over the past 30 years as a result of advances in prevention, detection, and treatment. However, competing risks for mortality from non-cancer causes have emerged, where cardiovascular disease (CVD) is now a leading cause of death for BC survivors. The direct toxic effects of BC treatment on the heart (cardiotoxicity) are well characterized by the investigators and many others, as a contributor to elevated cardiovascular risk. However, BC treatment and the associated lifestyle changes (i.e. physical inactivity, poor diet quality, stress) are increasingly recognized to also strongly affect metabolism negatively manifesting as insulin resistance, dyslipidemia and adipose tissue (fat) accumulation. These adverse metabolic changes are strongly linked to CVD risk and represent a currently underappreciated contributor to the elevated CVD risk among BC survivors. Preliminary data and recent publications demonstrate that regional fat accumulation occurs during BC treatment and that the fat burden in key locations is associated with poor cardiorespiratory health. A trigger of these adverse metabolic and inflammatory effects is excess fat specifically within ectopic fat (viscera, intermuscular, or hepatic) regions. In 2019, a member of the study team found that the volume of visceral and intermuscular but not subcutaneous fat at BC diagnosis were linearly associated with CVD events within 6 years, even among those with normal BMI and after adjustment for pre-existing CVD risk factors and for BC treatment type. Using MRI, investigators found that \~1 year after chemotherapy, BC survivors had significantly larger depots of visceral fat (49% larger) and thigh intermuscular fat (41% larger) compared to age and sex-matched controls, despite similar BMI and subcutaneous fat volumes in the two groups. Investigators also showed that the fat fraction within the thigh muscle and visceral fat volumes independently explained \~50% of the variation in cardiorespiratory fitness (measured by peak VO2). In particular, peak VO2 is one of the most powerful predictors of all-cause and CVD mortality and health care costs, and is the most consistently reported negative sequelae after treatment for BC. Unfortunately, there are no known therapies to recover long-term myocardial damage (i.e. cell death, fibrosis) from cancer therapies. There are several reasons to target fat as a therapeutic target in BC patients: 1) The study team have compelling preliminary data showing accelerated formation of ectopic fat during BC treatment. 2) Investigator's recent data showed that high fat content in key fat pools was associated with reduced peak VO2. 3) The burden of fat and the associated metabolic abnormalities are dynamic and malleable, and thus highly…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Time restricted eating, nutrition education, and sedentary time reduction strategies — 1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or "fast" by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week. 2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits. 3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life.

Primary Outcomes

  • Change in Fat Volumes (Baseline, 24-weeks, and 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-13
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Collaborators: Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Richard Thompson, PhD (PRINCIPAL_INVESTIGATOR) - University of Alberta
Contact Information
Study Contact:
Rachel Sherrington, Bkin
780-668-1669
rsherrin@ualberta.ca
Rachel Sherrington, Bkin
780-668-1669
rsherrin@ualberta.ca
University of Alberta
Richard Thrompson, PhD
University of Alberta
Interventions
  • Behavioral: Time restricted eating, nutrition education, and sedentary time reduction strategies — 1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or "fast" by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week. 2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits. 3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life.
Study Locations (2 sites)
University of Alberta, Edmonton, Alberta T6G2R3 Canada
University of Toronto, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * Female biological sex at birth * \>18 years * Diagnosis of stage I, II, or III breast cancer * starting neoadjuvant or adjuvant intravenous chemotherapy * ECOG \<3; * Oncologist approval to participate; * English speaking (all study materials and study staff will be in English) * Willing and able to adhere to study intervention Exclusion Criteria: * Individuals who do not have access to a smart phone with Bluetooth capability (required for Fitbit and for responding to intervention text messages) or at least a shared cell phone with someone in the same household (i.e., some couples may share a phone). * Type 1 or type 2 diabetes who require exogenous insulin (due to the potential need to adjust insulin dosing with TRE) or with hemoglobin A1c \>10% * Research MRI contraindications (e.g., pacemaker, magnetic implants, pregnancy) * Uncontrolled thyroid disorder * Self-reported eating disorder history * Body mass index \<18.5 kg/m2 or clinical signs of cachexia (discretion of treating oncologist) * ≥5% body weight loss within last 6 months * Those who are currently working night/rotating shifts, eating within ≤10-hour window or consistently eating less than 3 meals/day in the past 3 months. * patients who meet the criteria for medical clearance prior to exercise using the Physical Activity Readiness Questionnaire+ and are not cleared by their treating oncologist or family physician to perform maximal exercise testing.
Conditions Metastatic Triple-Negative Breast Carcin...
Phase PHASE1, PHASE2
Enrollment 20
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts. Previous to each phase inclusion, a specific ICF must be signed by the patient. Participants potentially eligible to participate in the clinical trial will be offered to sign a ICF three times prior to TILs treatment: 1) to allow for collection of archival FFPE tissue samples for determination PD1 by mRNA (Part #1), 2) prior to a fresh metastatic biopsy for selection, isolation and partial expansion of PD1+ TILs (Part #2) and 3) prior to allow for remaining study procedures and TILs therapy (Part #3, Main Consent).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PD1+ TILs (NUMARZU-001) product infusion — The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute. Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following: * Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion. * Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist. Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction).

Primary Outcomes

  • Incidence of grade 3-5 adverse event (AE) (24 weeks from the administration of PD1+ TILS (NUMARZU-001 product))
  • Overall response rate (ORR) (24 weeks from the administration of PD1+ TILS (NUMARZU-001 product))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2022-07-20
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundacio Clinic Barcelona
Collaborators: SOLTI Breast Cancer Research Group
Principal Investigators:
  • Aleix Prat (STUDY_CHAIR) - Hospital Clinic
  • Laura Angelats (STUDY_CHAIR) - Hospital Clinic
Contact Information
Study Contact:
Tomás Pascual
+ 34 933 436 302
tomas.pascual@gruposolti.org
Laura Angelats
LANGELATS@clinic.cat
Cristina Saura
Hospital Universitari Vall d'Hebrón
Interventions
  • Drug: PD1+ TILs (NUMARZU-001) product infusion — The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute. Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following: * Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion. * Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist. Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction).
Study Locations (4 sites)
Hospital Universitari Vall d'Hebrón, Barcelona, 08035 Spain
Hospital Clinic de Barcelona, Barcelona, 08036 Spain
Hospital 12 de Octubre, Madrid, 28041 Spain
Clínica universidad de Navarra, Pamplona, 31008 Spain
Eligibility Criteria
Eligibility criteria for Part #1 (Molecular pre-screening: Determination of PD1 by mRNA analysis from an archival FFPE tumor sample): Participants are eligible to be included in the study only if all of the following criteria apply: 1. Age ≥ 18 years. 2. Estimated life expectancy of ≥6 months. 3. Histologically confirmed diagnosis of unresectable or metastatic breast cancer. 4. Histologically confirmed diagnosis of advanced triple-negative breast cancer (based on the most recently analyzed biopsy from locally recurrent or metastatic site, local laboratory) meeting the following criteria: HER2-negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+, and ER and PgR expressions \<10% as determined locally by IHC assay as per most recent ASCO/CAP guidelines. 5. Patients could have received a maximum of 5 lines of prior standard of care chemotherapy in the inoperable/metastatic setting. 6. Patients must not have history of other malignancy within the past 3 years with the following exceptions: adequately treated non-melanoma skin cancer without evidence of disease at the time of enrollment; adequately treated cervical carcinoma in situ without evidence of disease at the time of enrollment; adequately treated breast ductal carcinoma in situ without evidence of disease at the time of enrollment; prostatic intraepithelial neoplasia without evidence of prostate cancer at the time of enrollment; adequately treated superficial or in-situ carcinoma of the bladder without evidence of disease at the time of enrollment. 7. Subject likely to be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge. 8. Absence of psychiatric or physiologic history, substance abuse, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 9. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 10. Pregnant or breastfeeding women will NOT be eligible. 11. Subject has known sensitivity to any of the products or components to be administered during dosing will NOT be eligible. 12. NOT having an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved in this trial, unless prospective institutional review board (IRB)/independent ethics committee (IEC) approval (by chair or designee) is given allowing an exception to this criterion for a specific subject 13. Patients must NOT have undergone prior allogeneic hematopoietic stem cell transplantation 14. Patients with a history or evidence of symptomatic autoimmune will NOT be eligible: glomerulonephritis, vasculitis, or other symptomatic autoimmune diseases, or active autoimmune disease or syndrome that has required systemic treatment in the past 2 years (ie, with the use of disease-modifying agents, corticosteroids or immunosuppressive drugs) except vitiligo or resolved childhood asthma/atopy. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 15. Absence of active bacillus tuberculosis history. 16. Absence of a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required. 17. Absence of a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required. 18. To be able to provide either a newly obtained tumor biopsy (preferred) or archival tumor tissue of an FFPE tumor block. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for gene expression analysis prior to enrollment in Part #2. Eligibility criteria for Part #2 (Pre-Screening Phase: Selection, isolation and partial expansion of PD1+ TILs from a fresh tumor sample): Participants are eligible to be included in the study only if all the previous and the following criteria apply: 1. Patients will be eligible for Part #2 if they have a PD-1 mRNA expression above the 20th percentile in the FFPE tumor sample analyzed in Part 1. 2. At least 1 resectable target lesion 3. Patients must NOT have clinically active cerebral metastases. Carcinomatous meningitis is not allowed regardless of clinical stability. Eligibility criteria for Part #3 (Screening and treatment Phase: Complete expansion of PD1+TILs. Treatment of patients with PD1+ TILs infusion): Participants are eligible to be included in the study only if all of the previous and the following criteria apply. For being included in this section, the following criteria must apply: 1. PD1+ TILs selection in Part #1 and successful partial expansion of tumor sample in Part #2 2. Treatment-related toxicities (except alopecia and neuropathy G2) must ≤ Grade 1 at the time of allocation according to CTCAE version 5.0. 3. All patients must have received two or more prior systemic therapies, including at least one of them for advanced disease and an ADC. A maximum of five chemotherapy-based lines are permitted in the metastatic setting. Prior treatment should be discontinued 28 days or 5 half-lives, whichever is shorter, before day 1 of NMA-LD. 4. Measurable disease according to RECIST 1.1 criteria. 5. Adequate organ function determined within 28 days prior to enrollment. 6. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to enrollment. 7. For patients ≥ 60 years or patients who have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias, a cardiac stress tests must be performed showing normal LVEF, NYHA functional classification \< class 1 and if any wall movement abnormalities, they must be reversible. 8. Left ventricular ejection fraction (LVEF) ≥ 50% at baseline as determined by either ECHO or MUGA 9. Patients must not be currently receiving treatment with another investigational device or drug study. No other investigational procedures (of any kind) are permitted while participating in this study. 10. Systemic steroid therapy is not permitted (patients who require replacement therapy for adrenal insufficiency may be enrolled if the steroid treatment dose does not exceed 10 mg of prednisone or equivalent). 11. Patients with evidence of clinically significant immunosuppression will NOT be eligible. 12. Patients with evidence of (non-infectious) pneumonitis that required steroids or current pneumonitis will NOT be eligible.